Evidence map›Paper›PMID 37989332›Full record

ArticleBMJ case reports2023

Hodgkin lymphoma associated vanishing bile duct syndrome treated successfully with a brentuximab based regimen.

Judah D Morgan, Robert C Weishar, Ryan M Kwok, Kenneth M Lieuw

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review of Paraneoplastic Syndromes in Children with Malignancy.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Judah D MorganInternal Medicine, Madigan Army Medical Center, Tacoma, Washington, USA.
Robert C WeisharMedicine, Uniformed Services University of the Health Sciences F Edward Hebert School of Medicine, Bethesda, Maryland, USA robert.weishar@usuhs.edu.
Ryan M KwokHepatology, Madigan Army Medical Center, Tacoma, Washington, USA.
Kenneth M LieuwPediatric Oncology, Madigan Army Medical Center, Tacoma, Washington, USA.
Madigan Army Medical Center · USUniformed Services University of the Health Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a combination therapy to successfully treat a patient with Hodgkin's lymphoma complicated by vanishing bile duct syndrome. Our patient was in his 20s and presented with jaundice, emesis, B symptoms and diffuse lymphadenopathy along with cholestatic liver injury prompting a liver biopsy, which revealed this diagnosis, after the exclusion of other aetiologies. Our treatment regimen incorporated brentuximab along with other more conventional agents which attempted to maximise therapeutic efficacy while minimising the consequences of hepatotoxicity on the treatment protocol. Although this patient's treatment course was complicated because of neutropenic infections, the patient achieved a complete metabolic response and is now more than 1 year off therapy.

Indexed as

Antineoplastic AgentsCholestasisHodgkin DiseaseAdultAntibodies, MonoclonalBile DuctsClinical ProtocolsHumansLiverMaleAntibodies, MonoclonalAntineoplastic AgentsCancer interventionGastroenterologyPaediatric oncology

Identifiers

PMID37989332
PMCPMC10668144
OpenAlexW4388871136

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.